Wednesday, January 17, 2024 12:18:46 PM
ILT,
People are smart. They can only be fooled once or twice. The declining numbers tell the real story.
https://www.cdc.gov/respiratory-viruses/data-research/dashboard/vaccination-trends-adults.html
I don't believe that Merck would pin its future on the mRNA stuff. It is highly risky. How could they find all the neopeptides that can trigger immune response? I feel like those specific type of neopeptides are as rare as diamond.
Here are the constructions of all the facilities at West Point. They were started in November. I don't think at the time that Merck made the decision on construction Merck had conclusive results on the trial of keytruda + mRNA.
https://www.uppergwynedd.org/board-commissioners/files/nov-2021-merck-63a-presentation
https://www.uppergwynedd.org/board-commissioners/files/oct-19-merck-presentation-b45
https://www.uppergwynedd.org/board-commissioners/files/feb-2021-merck-b50-presentation-0
https://www.uppergwynedd.org/board-commissioners/files/april-12-merck-b32-presentation
People are smart. They can only be fooled once or twice. The declining numbers tell the real story.
Vaccination Trends Update:
The percent of the population reporting receipt of COVID-19, influenza, and RSV vaccines remains low for adults. Estimates for children will be updated next week.
The percent of the population reporting receipt of the updated 2023-24 COVID-19 vaccine is 21.4% (20.6-22.2) for adults 18+, including 41.5% (39.3-43.8) among adults age 65+.
The percent of the population reporting receipt of a flu vaccine is 46.8% (45.7-47.9) for adults 18+, including 74.1% (71.3-76.9) among adults age 65+.
The percent of adults age 60+ that report receiving an RSV vaccine is 20.1% (18.8-21.4).
Reported on Friday, January 12th, 2024..
https://www.cdc.gov/respiratory-viruses/data-research/dashboard/vaccination-trends-adults.html
I don't believe that Merck would pin its future on the mRNA stuff. It is highly risky. How could they find all the neopeptides that can trigger immune response? I feel like those specific type of neopeptides are as rare as diamond.
Here are the constructions of all the facilities at West Point. They were started in November. I don't think at the time that Merck made the decision on construction Merck had conclusive results on the trial of keytruda + mRNA.
https://www.uppergwynedd.org/board-commissioners/files/nov-2021-merck-63a-presentation
https://www.uppergwynedd.org/board-commissioners/files/oct-19-merck-presentation-b45
https://www.uppergwynedd.org/board-commissioners/files/feb-2021-merck-b50-presentation-0
https://www.uppergwynedd.org/board-commissioners/files/april-12-merck-b32-presentation
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
